Outcomes After Acute Respiratory Failure in Patients With Interstitial Lung Disease
Abstract
Background: Interstitial lung diseases (ILDs) are a heterogeneous group of pulmonary disorders that can result in acute or chronic forms of respiratory failure. Prior studies have shown high mortality among patients with ILD receiving intensive care, but most have focused on idiopathic pulmonary fibrosis (IPF) and have not characterized other ILD subgroups.
Research question: Does 90-day transplant-free survival differ by ILD subgroup in patients with acute respiratory failure (ARF) requiring respiratory support?
Study design and methods: We conducted a retrospective cohort study of adults with ILD admitted to 5 hospitals within our health system (2017-2024) using electronic record health data. We pragmatically defined ARF as receipt of ≥ 24 continuous hours of invasive or noninvasive respiratory support. We identified ILD diagnosis using validated International Classification of Diseases, version 10, Clinical Modification codes categorized into IPF/idiopathic interstitial pneumonia, connective tissue disease-associated ILD (CTD-ILD), exposure-related ILD, sarcoidosis, or other ILD. We evaluated 90-day transplant-free survival with multivariable Cox proportional hazards models adjusted for demographics, comorbidities, hospital type, and acute illness severity. Secondary outcomes included in-hospital death or hospice discharge and hospital length of stay.
Results: Among 982 patients with ILD and ARF (median age, 70 years; 50% female), 269 (27%) were categorized as…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 982 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.